Phase II Trial of Erlotinib Plus Concurrent Whole-Brain Radiation Therapy for Patients With Brain Metastases From Non–Small-Cell Lung Cancer

PURPOSE: Brain metastasis (BM) is a leading cause of death from non–small-cell lung cancer (NSCLC). Reasoning that activation of the epidermal growth factor receptor (EGFR) contributes to radiation resistance, we undertook a phase II trial of the EGFR inhibitor erlotinib with whole-brain radiation t...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Welsh, James W., Komaki, Ritsuko, Amini, Arya, Munsell, Mark F., Unger, Wyatt, Allen, Pamela K., Chang, Joe Y., Wefel, Jeffrey S., McGovern, Susan L., Garland, Linda L., Chen, Su S., Holt, Jamie, Liao, Zhongxing, Brown, Paul, Sulman, Erik, Heymach, John V., Kim, Edward S., Stea, Baldassarre
Format: Artigo
Idioma:Inglês
Publicat: American Society of Clinical Oncology 2013
Matèries:
Original Reports
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3577951/
https://ncbi.nlm.nih.gov/pubmed/23341526
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2011.40.1174
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars